Tocilizumab is indicated for the treatment of moderate to severe rheumatoid arthritis, giant cell arteritis, and other inflammatory conditions, as well as for cytokine release syndrome (CRS). It works by blocking interleukin-6 (IL-6) receptors, a key pathway driving inflammation. Its main advantage is rapid and targeted suppression of excessive inflammatory response, which helps control symptoms, prevent tissue damage, and improve clinical outcomes. In hospital settings, particularly in severe inflammatory states or CRS, tocilizumab can quickly reduce fever, inflammatory markers, and organ dysfunction. It is also widely used when patients have inadequate response to conventional therapies. Its targeted mechanism and strong efficacy make it an important biologic therapy in rheumatology and critical care.